| Q57166498 | An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when |
| Q89402908 | Applications of PET-MRI in musculoskeletal disease |
| Q52597352 | Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET/CT imaging. |
| Q42374278 | Automatic digital quantification of bone marrow myeloma volume in appendicular skeletons - clinical implications and prognostic significance |
| Q42388536 | Baseline bone involvement in multiple myeloma - a prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients |
| Q61755936 | Clinical Applications of Nuclear Medicine: Multiple Myeloma |
| Q64929020 | Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. |
| Q89715025 | Computed tomography-based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma |
| Q38789282 | Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials |
| Q61755927 | Diagnostic Applications of Nuclear Medicine: Multiple Myeloma |
| Q92030406 | Dual-tracer PET/CT scan after injection of combined [18 F]NaF and [18 F]FDG outperforms MRI in the detection of myeloma lesions |
| Q47697058 | Functional and molecular MRI of the bone marrow in multiple myeloma |
| Q47329918 | Guidelines for the use of imaging in the management of patients with myeloma |
| Q64063183 | Interest of Pet Imaging in Multiple Myeloma |
| Q38832525 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma |
| Q92510769 | International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders |
| Q37701511 | Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. |
| Q50092746 | Minimal residual disease analysis in myeloma - when, why and where. |
| Q38895092 | Multiple myeloma: disease response assessment |
| Q43065347 | New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma |
| Q90383109 | Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time? |
| Q37691050 | PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients |
| Q90260579 | PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues |
| Q92442102 | Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma |
| Q39214847 | Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group |
| Q91791994 | Serum free light chains and multiple myeloma: Is it time to extend their application? |
| Q89777986 | Should minimal residual disease negativity not be the end point of myeloma therapy? |
| Q39410899 | Standardisation of minimal residual disease in multiple myeloma |
| Q58609425 | Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling |
| Q39264310 | The possible role of burden of therapy on the risk of myeloma extramedullary spread |
| Q48089815 | Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. |
| Q61905637 | Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma |
| Q37593761 | Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response |